Treatment with lenvatinib to anaplastic thyroid cancer :

Abstract

Anaplastic thyroid cancer(ATC)is one of the most aggressive cancers in humans. Typical therapeutic approaches for malignant neoplasms such as surgery, radiotherapy, chemotherapy and combination therapy have been tried as a radical or palliative therapy for ATC patients, but outcomes are extremely poor. Recently, lenvatinib, which is a multi-targeted tyrosine kinase inhibitor, was approved as a new therapeutic drug for ATC. Here we report a case of ATC treated by lenvatinib.